Azmasol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azmasol

Property Description
Active ingredient Salbutamol (Albuterol)
Form Pressurized inhalation aerosol (MDI)
Pharmacological class Short-acting beta2-adrenoceptor agonist (SABA)
General purpose Rapid relief from breathing difficulty
Origin Synthetic

Defining Azmasol: Identity and Pharmacological Class

Azmasol is a pharmaceutical preparation whose active substance is Salbutamol, a synthetic compound internationally recognized also by the name Albuterol in the United States. It is formally classified as a short-acting beta2-adrenoceptor agonist (SABA), belonging to the sympathomimetic amine derivatives. This SABA classification denotes the medicine's role as a dedicated rapid-relief medication used to counteract sudden airway constriction. The efficacy and short action profile of Salbutamol characterize its standard role in acute relief within respiratory medicine.


Composition, Origin, and Delivery Form

The active ingredient in Azmasol is typically present as Salbutamol Sulphate, which is entirely synthetic in origin. While Salbutamol is available for oral ingestion, the most common dosage form of Azmasol is the pressurized inhalation aerosol delivered via a metered-dose inhaler (MDI). This delivery mechanism ensures the medication is administered directly to the bronchial smooth muscle for a rapid and concentrated local therapeutic effect, which is a fundamental principle of respiratory drug delivery. Azmasol, like other Salbutamol MDIs, is designated as a prescription-only medicine (POM) due to its bronchodilator action.


General Purpose and Mechanism of Relief

The fundamental purpose of Azmasol is to act as a bronchodilator, providing prompt symptomatic relief from acute breathing difficulty. Its action is based on stimulating beta2-adrenergic receptors located in the airway walls, which triggers the relaxation of the smooth muscles surrounding the bronchial tubes. By easing this muscular constriction, Azmasol opens the narrowed air passages, restoring airflow and alleviating the sensation of chest tightness or wheezing. A typical use scenario involves using Azmasol to quickly alleviate a sudden episode of bronchospasm which may cause respiratory distress.

Regulatory References

  1. MedlinePlus: Salbutamol Inhalation

What side effects are possible with Azmasol?

Official Safety Profile and Adverse Reactions

The safety profile of Azmasol (Salbutamol/Albuterol inhalation) is formally structured by regulatory authorities based on the frequency and physiological impact of documented adverse reactions. These effects primarily relate to the medication's stimulating action on the cardiovascular and nervous systems.

Classification Examples of Reported Effects
Common (ge 1/100 to < 1/10) Tremor, Headache, Tachycardia (fast heart rate).
Uncommon (ge 1/1000 to < 1/100) Palpitations, Muscle cramps, Mouth and throat irritation.
Rare (ge 1/10,000 to < 1/1000) Hypokalaemia (low potassium), Peripheral vasodilatation.
Very Rare (< 1/10,000) Hypersensitivity reactions (e.g., angioedema, collapse), Paradoxical bronchospasm.

Serious adverse reactions, though classified as very rare, include paradoxical bronchospasm—an immediate, life-threatening worsening of breathing difficulty—and specific cardiac arrhythmias or myocardial ischaemia. The official labeling notes that common effects like tremor are often transient and may diminish with continued treatment.

Safety-Related Constraints

Regulatory documents emphasize that caution is required when Azmasol is used in individuals with pre-existing conditions sensitive to sympathomimetic agents, including hypertension, coronary insufficiency, cardiac arrhythmias, thyrotoxicosis, and diabetes mellitus. In the pediatric population, specific behavioral changes such as hyperactivity and restlessness have been documented. Furthermore, an increasing reliance on or excessive use of this medicine is recognized by regulators as a sign of deteriorating disease control.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Azmasol (Salbutamol/Albuterol) is officially characterized by manifestations resulting from excessive sympathomimetic activity. Documented clinical signs include tachycardia ( rapid heartbeat), palpitations, tremor, nervousness, headache, and dizziness. Physiological disturbances like hypokalemia ( low potassium) and hyperglycemia ( high blood sugar) are also documented findings in regulatory information. Excessive use of inhaled sympathomimetic drugs is associated with severe cardiac events and may lead to fatalities, as stated in the official prescribing information.


Mandated Emergency Intervention

In the event of suspected drug overdose, immediate emergency intervention is mandated. Official guidance requires that you seek emergency medical attention immediately and contact emergency services or a Poison Control Centre without delay, even if symptoms are not yet apparent.

Treatment focuses on symptomatic and supportive measures. Regulatory documents specify that hospital monitoring may be required, including continuous monitoring of vital signs and serum potassium levels to manage documented metabolic risks.

Therapeutic Uses of Azmasol

Azmasol is generally used as a rescue medication applied in clinical settings that involve acute or unstable symptom patterns related to airway narrowing in conditions like asthma and Chronic Obstructive Pulmonary Disease (COPD). This medication is commonly used to treat and prevent symptoms related to difficulty breathing, wheezing, and chest tightness caused by these lung diseases. It is relevant for easing acute bronchospasm, managing exacerbations of COPD, and preventing Exercise-Induced Bronchospasm (EIB).

This medication may assist with easing the most distressing symptoms often accompanying an exacerbation. It is applied when symptoms create noticeable physiological strain, offering symptomatic relief that supports the patient during difficult episodes. The core benefit is the support provided to ease symptoms related to physical discomfort, which helps stabilize symptoms during phases where the patient experiences heightened distress. This support contributes to a sense of stability when symptoms become more noticeable.

Quick Fact: Relief for Acute Constriction
Primarily used as a rescue measure for sudden, episodic symptoms related to heightened physiological activity used in situations involving certain distressing symptoms.

Regulatory References

  1. NIH MedlinePlus overview of Albuterol Oral Inhalation

Eligibility and Restrictions for Use

Azmasol is officially approved for use in adults and adolescents aged 12 years and older, as well as in children aged 4 years and older. The safety and effectiveness of the pressurized inhalation aerosol form are not established in children younger than 4 years of age.


Contraindications

Use of Azmasol is contraindicated (must not be used) in patients with a documented history of hypersensitivity to albuterol (salbutamol) or to any other component of the specific formulation. It is also prohibited for obstetric use, such as for the management of threatened abortion or premature labor.


Conditional Use and Restrictions

Official regulatory documents stipulate that Azmasol must be used with caution in patients with certain pre-existing conditions:

  • Cardiovascular Disorders: Includes individuals with coronary insufficiency, cardiac arrhythmias, or hypertension.
  • Endocrine and Metabolic Conditions: Includes patients with hyperthyroidism (an overactive thyroid), diabetes mellitus, or convulsive disorders.

Pregnancy and Lactation: Azmasol is classified as Pregnancy Category C. Use during pregnancy or breastfeeding is generally not recommended unless the potential benefit justifies the potential risk to the fetus or infant, as determined by regulatory risk classification.

What should I know about interactions with other medicines?

Azmasol Interactions with other medicines and products

Azmasol (Salbutamol) has formally documented interaction patterns primarily related to its sympathomimetic classification. Regulatory agencies identify specific co-administered medicinal products that necessitate restrictions or extreme caution due to pharmacokinetic and pharmacodynamic effects.


Mandatory Co-administration Restrictions

The co-administration of Azmasol with non-selective beta-adrenergic receptor blocking agents is generally not recommended. These agents produce pharmacodynamic antagonism by blocking the pulmonary effect of Azmasol, which is officially documented to carry the risk of precipitating severe bronchospasm. Furthermore, other short-acting sympathomimetic aerosol bronchodilators and Epinephrine should not be used concomitantly, as stated in regulatory information.


Potentiation and Additive Risk

Extreme caution is required when administering Azmasol to patients using Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs), or within two weeks of their discontinuation. This restriction is due to the documented potential for potentiating the action of Azmasol on the vascular system. An additive risk of hypokalemia (low blood potassium) is also officially associated with the concurrent use of Azmasol and agents like Non-Potassium-Sparing Diuretics (e.g., loop or thiazide diuretics), Corticosteroids, and Xanthine Derivatives. Additionally, Azmasol administration is formally documented to cause a mean decrease in the serum levels of Digoxin, reflecting a change in the plasma exposure of the co-administered drug. No specific interaction patterns involving food, alcohol, or herbal products are explicitly documented in major government regulatory labels.

Mechanism of Action

Azmasol is a direct-acting beta2-adrenoceptor agonist. It exerts its effect by binding selectively to beta2-adrenergic receptors located predominantly on the smooth muscle cells of the airways. Agonist binding initiates a transmembrane signal cascade involving the stimulatory G-protein, G s. This interaction activates the enzyme adenylate cyclase, catalyzing the conversion of adenosine triphosphate (ATP) to the second messenger, cyclic adenosine monophosphate (cAMP).

The resulting elevated intracellular cAMP levels activate protein kinase A (PKA). PKA, in turn, phosphorylates various target proteins, ultimately modulating intracellular calcium ( Ca^2+) handling. This molecular sequence leads to the inhibition of myosin light chain phosphorylation, causing a reduction in muscle contractile force and a corresponding decrease in smooth muscle tone within the targeted pathways.

Dosage and Administration Information

Azmasol (albuterol sulfate) is a quick-relief bronchodilator inhalation aerosol typically delivered via a metered-dose inhaler (MDI). It is for oral inhalation only and should be used exactly as prescribed by a healthcare provider.

Administration

Indication Recommended Dosage (Adults and Children ≥ 4 years old) Timing
Treatment/Prevention of Bronchospasm 2 inhalations (180 mcg) Every 4 to 6 hours, as needed
Prevention of Exercise-Induced Bronchospasm 2 inhalations (180 mcg) 15 to 30 minutes before exercise
  • Do not exceed the recommended dose. More frequent use or a greater number of inhalations may indicate a worsening of your condition and requires immediate medical attention.

Priming and Technique

  1. Priming: If the inhaler is new or has not been used for more than two weeks, it must be primed. To prime, shake the inhaler well and release three test sprays into the air, away from your face.
  2. Inhalation: Shake the inhaler well before each use. Breathe out fully. Place the mouthpiece into your mouth and close your lips around it. Press down on the canister while breathing in slowly and deeply.
  3. Holding Breath: Hold your breath for up to 10 seconds, then breathe out slowly.
  4. Multiple Puffs: If a second inhalation is prescribed, wait at least one minute before repeating the steps, starting with shaking the inhaler again.

After use, rinse your mouth with water and spit it out to help reduce the potential for side effects in the mouth and throat. Clean the plastic actuator (mouthpiece) at least once per week with warm running water to prevent blockage.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azmasol

Evidence for Acute Relief of Bronchospasm in Asthma

Azmasol was evaluated in research exploring its influence on short-term symptom patterns in individuals, including both adults and children, who experience acute breathing difficulty related to asthma. Research in this area is extensive, consisting of many Randomized Controlled Trials (RCTs) and comprehensive systematic reviews that date back several decades. These studies were conducted during periods of increased symptom activity and typically examined how quickly key physiological measures, such as the maximum air expelled in one second (FEV1), change over time following administration.

The trials reported measurements of lung function, with the onset of measured change often occurring within a few minutes of use. Findings from the studies describe patterns observed where the measured changes in airflow peaked shortly thereafter, within the defined time points of the studies.

Evidence for Prevention of Exercise-Induced Bronchospasm (EIB)

Research examined the influence of Azmasol on outcomes describing episodic changes in breathing function that can be associated with physical exertion. These studies often used a crossover design and were evaluated in individuals with documented Exercise-Induced Bronchospasm (EIB). The typical research scenario involved measuring lung function both before and after a standardized exercise challenge.

Trials reported measurements of the percent fall in lung function following the standardized challenge after pre-treatment of the airways. Findings describe patterns indicating that the observed changes were temporary, returning to pre-study levels within the observed time intervals. The evidence base in this area is generally limited to acute, single-dose assessments.

Key Limitations and What Remains Uncertain

Research highlights the available evidence and the areas of uncertainty. One of the key limitations in the evidence is the scarcity of data related to long-term outcomes when the medicine is used regularly rather than strictly for acute, episodic symptom relief. Furthermore, studies on long-term, high-frequency use was associated with patterns whose consequences are not yet fully established, and more research is needed to understand these findings. Evidence quality varies across studies, particularly in the COPD context where comparative evidence is lacking in some modern trial settings. Research does not determine whether an individual will respond similarly; the study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines (Used for long-term/overuse risk and observational data)

Frequently Asked Questions (FAQ)

Common questions about Azmasol (FAQ)


Q: Is it possible to become dependent on Azmasol?

Official product information indicates that an increased need for this medication or the use of more than the usual number of doses should be viewed as a sign of deteriorating disease control. This pattern is a clinical sign that warrants review by a healthcare provider.


Q: Is Azmasol safe for women who are planning pregnancy?

Studies evaluating the effect of the inhaled drug on human fertility have not been conducted. However, research in animals has indicated no effect on fertility. It is customary to review medication plans with a healthcare provider during the preconception phase to ensure proper management of the underlying condition.


Q: What does the drug's safety classification (e.g., in pregnancy) indicate?

The official Pregnancy Category C designation, as defined by regulatory bodies, means that animal studies have shown potential adverse effects on the fetus, and there are no sufficient studies in humans. The decision for use is made by a healthcare provider, balancing the potential benefit against the potential risks, as described by the regulatory classification.


Q: Do people take Azmasol for conditions other than [main use]?

According to the official product labeling, this medication is approved by the FDA strictly for treating and preventing acute or severe bronchospasm in patients with reversible obstructive airway disease. This includes use for exercise-induced bronchospasm (EIB).


Q: How long does the effect of one use of Azmasol typically last?

Official information on the drug's action indicates that the effect of a single use typically lasts for 4 to 6 hours. If symptom relief is insufficient or the duration of action shortens, this may signal a deterioration of the underlying condition.


Q: Does Azmasol cause changes in sleep patterns?

Regulatory documents list insomnia (difficulty sleeping) as a reported adverse reaction of the drug. This information is found in the official safety profile sections.


Q: Can Azmasol affect my mood or energy levels?

Official safety information includes asthenia as a reported adverse reaction. Asthenia is a term used to describe unusual weakness or a lack of energy.


Q: Is it okay to drink coffee or caffeine while using Azmasol?

The medication is associated with cardiovascular effects, such as increases in heart rate and blood pressure. Its co-administration with other stimulating agents, such as caffeine, is an area that requires professional consideration.


Q: Is Azmasol safe for use in older adults (seniors)?

Official studies have not demonstrated specific problems in the geriatric population that would limit the usefulness of the drug. However, because older adults are more likely to have age-related issues with the heart, liver, or kidneys, caution is generally warranted due to potential age-related organ changes. Any necessary adjustments should be determined by a healthcare provider.


Q: Why does Azmasol need to be taken in a specific way?

The specific steps for inhalation and priming (preparing the inhaler) are required to ensure that the proper amount of medicine is delivered directly to the lungs. Following the prescribed technique helps to ensure the medication works as intended.


Q: What should I do if I miss a usage of Azmasol?

Official guidance for a regularly scheduled treatment advises that the missed dose be taken as soon as possible. If it is near the time for the next scheduled dose, the missed dose should be skipped, and only the next scheduled dose should be taken. Double or extra doses should not be taken to compensate for a missed one.


Q: How is Azmasol different from a steroid medicine?

Official labeling specifies that this medication is not a substitute for anti-inflammatory agents such as inhaled or oral corticosteroids. It functions differently and cannot replace other medications designed to control inflammation.


Q: Can people with kidney problems use Azmasol?

Use in individuals with kidney disease is generally associated with a regulatory caution. This is because official documents indicate that the effects of the drug may be increased due to the body's slower removal of the medicine.


Q: What is the physical appearance of Azmasol (color, size, form)?

The medication is a pressurized inhalation aerosol delivered through a metered-dose inhaler (MDI). This device is typically a blue plastic actuator with a matching cap, containing the medicine canister inside.


Q: Are there generic versions of Azmasol available?

Yes, the active drug, Albuterol Sulfate HFA inhalation aerosol, is available from multiple manufacturers as a generic that is approved by regulatory bodies.


Q: Does Azmasol contain any common allergens, like gluten or dairy?

Some formulations of the medication, specifically certain dry powder inhalers, have been documented to contain an excipient derived from milk protein. Regulatory documents indicate that these specific formulations are contraindicated for patients with a known history of milk protein allergy.


Q: Are the side effects of Azmasol dose-dependent?

The official safety warnings link the most serious adverse effects, including clinically significant cardiovascular effects, with the excessive use of the inhaled drug. This indicates that using more than the recommended amount may increase the potential for severe reactions.

How should Azmasol be stored and disposed of?

How to Store and Dispose of Azmasol

Official regulatory guidelines for Azmasol (Albuterol Inhalation Aerosol) govern its storage and disposal, focusing on temperature control and canister safety.

Requirement Type Official Instructions
Storage Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Avoid extremes.
Prohibited Conditions Do not freeze the canister. Do not expose to temperatures above 49 C (120 F) as the pressurized contents may burst.
Protection & Handling Protect from direct sunlight. Keep the canister out of reach of children. Do not puncture or use near heat or open flame.
Disposal Do not dispose of the empty or unused inhaler in household trash or incinerate it. Utilize official drug take-back programs or local community hazardous waste collection sites, as the pressurized canister and propellant require special handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azmasol found in:

A-Z Index: